Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.

Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: N.Y. reports honoraria from AstraZeneca, outside of the submitted work. W.C. reports honoraria from AstraZeneca, Janssen, Merck, Pfizer; research grant funding from the Breast Cancer Trials group; and the Australian Government Research Training scholarship, outside of the submitted work. S.P. reports personal fees from AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, Novartis, Takeda, BMS, MSD, EMD Serono, Bayer, Blueprint, Daiichi Sankyo, Guardant Health, Janssen, GSK, BeiGene, Incyte, Eli Lilly, Amgen, outside the submitted work. Others declare no conflict of interest.